Evidence map›Paper›PMID 28721684›Full record

ArticleEJNMMI research2017

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model.

Jessie R Nedrow, Anders Josefsson, Sunju Park, Tom Bäck, Robert F Hobbs, Cory Brayton, Frank Bruchertseifer, Alfred Morgenstern, George Sgouros

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Gamma counting protocols for the accurate quantification ofEJNMMI radiopharmacy and chemistry · 2022
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. B7-H3-targeted Radioimmunotherapy of Human Cancer.Current medicinal chemistry · 2020
    Review
  16. Alpha radioimmunotherapy usingTheranostics · 2020
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Jessie R NedrowRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, CRBII 4M.61, 1550 Orleans Street, Baltimore, MD, 21231, USA.
Anders JosefssonRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, CRBII 4M.61, 1550 Orleans Street, Baltimore, MD, 21231, USA.
Sunju ParkRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, CRBII 4M.61, 1550 Orleans Street, Baltimore, MD, 21231, USA.
Tom BäckThe Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Robert F HobbsDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Cory BraytonDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Frank BruchertseiferEuropean Commission Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Alfred MorgensternEuropean Commission Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
George SgourosRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, CRBII 4M.61, 1550 Orleans Street, Baltimore, MD, 21231, USA. gsgouros@jhmi.edu.
Johns Hopkins University · USJoint Research Centre · DEUniversity of Gothenburg · SE

Funding

Combined Biologic and Radiopharmaceutical Therapy of Breast CancerR01CA187037 · NCI · JOHNS HOPKINS UNIVERSITY · PI SGOUROS, GEORGE · 2015 to 2019
$2.4M
Modeling Targeted Alpha Particle Therapy of CancerR01CA157542 · NCI · JOHNS HOPKINS UNIVERSITY · PI HOBBS, ROBERT FRANCOIS · 2012 to 2015
$1.3M
NCI NIH HHS R01 CA157542NCI NIH HHS R01 CA187037
6 · The paper itself

Abstract

backgroundStudies combining immune checkpoint inhibitors with external beam radiation have shown a therapeutic advantage over each modality alone. The purpose of these works is to evaluate the potential of targeted delivery of high LET radiation to the tumor microenvironment via an immune checkpoint inhibitor.

methodsThe impact of protein concentration on the distribution of

resultsThe evaluation of

conclusionsThese studies demonstrate that

Indexed as

Alpha-particle emitting radioimmunotherapyAnti-PD-L1 antibodiesDosimetryImmune checkpoint inhibitionPharmacokinetics

Identifiers

PMID28721684
PMCPMC5515722
OpenAlexW2737984187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.